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S
troke is an important contributor to death and major disability worldwide. Ischemic stroke is by far the most common subtype of stroke in China. 1 Atherosclerosis and inflammation reaction had been thought to be contributed to the pathogenesis of ischemic stroke. 2 galectin-3-a protein that plays roles in adhesion and proliferation of cells and immune response-was suggested to be associated with inflammation and atherosclerosis. 3, 4 Some clinical studies had found significant associations between elevated levels of galectin-3 and poor outcomes in patients with heart failure. 5 Animal study showed the upregulated expression of galectin-3 in the ischemic brain of experimental rats. 6 However, it is less known whether galectin-3 has any effect on poor outcomes of ischemic stroke in human population. Therefore, the aim of the present study was to examine the association of galectin-3 with poor clinical outcomes in a large cohort of patients with acute ischemic stroke.
Methods
This study was conducted based on the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). Details of the trial design and methods have been presented elsewhere (File I in the online-only Data Supplement). 7 Among 4071 patients with ischemic stroke recruited in CATIS, 989 patients were excluded because they did not offer qualified blood samples in this study (Table I in the online-only Data Supplement). Finally, 3082 participants were included in this analysis. This study was approved by the Institutional Review Boards at Soochow University in China and Background and Purpose-Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure. However, it remains unclear whether galectin-3 has any effect on the poor outcomes of ischemic stroke. The aim of the present study was to examine the association between galectin-3 with poor outcomes among patients with acute ischemic stroke. Methods-Serum galectin-3 was measured in 3082 patients with acute ischemic stroke. The primary outcome was a combination of death or major disability (modified Rankin Scale score, ≥3) at 3 months after stroke. Results-Compared with the lowest quartile of galectin-3, multivariate adjusted odds ratios (95% confidence intervals)
for the highest quartile of galectin-3 were 1. Tulane University in the United States, as well as ethics committee at each study center. Written informed consent was obtained from all study participants or their legal proxies. Baseline data, including demographic characteristics, clinical characteristics, medical histories, and lifestyles, were collected. National Institutes of Health Stroke Scale was used to evaluate stroke severity at enrollment. Galectin-3 levels at baseline were measured for all participants using a commercially available ELISA kit (R&D Systems, Minneapolis, MN). The Intra-assay coefficient of variation for this assay is ≤3.6%, and the interassay coefficient of variation is ≤6.1%.
The primary outcome was defined as a combination of death and major disability (scores 3-6 of modified Rankin Scale [mRS]) at 3 months after stroke onset. Secondary outcomes were separately those of death and major disability (mRS scores of 6 and 3-5, respectively) and an ordered 7-level categorical score of the mRS.
Study participants were divided into 4 subgroups according to quartiles of galectin-3 levels. Logistic regressions were applied to assess the association between galectin-3 levels with study outcomes, and restricted cubic splines were used to examine the shape of the association. 8 The sensitivity analysis was conducted by excluding the patients with history of coronary heart disease. C statistics, 9 net reclassification indexes, and integrated discrimination improvement indexes 10 were calculated to evaluate improvement in risk classification by galectin-3 over conventional risk factors. Two-sided P<0.05 was used as a significance level. All statistical analyses were performed using SAS statistical software (version 9.4; Cary, NC).
Results
Baseline characteristics of patients according to quartiles of galectin-3 are shown in Table II in the online-only Data Supplement.
As shown in Table 1 , after multivariable adjustment, odds ratios (95% confidence intervals) for the highest quartile of galectin-3 were 1.55 (1.15-2.09) for primary outcome, 2.10 (0.89-4.95) for death, 1.43 (1.05-1.93) for major disability, and 1.63 (1.31-2.03) for 1-U higher mRS score, compared with the lowest quartile of galectin-3. Every 1-SD increase of galectin-3 level was also positively associated with poor outcomes among patients with ischemic stroke. Multivariable adjusted spline regression models suggested a linear association of galectin-3 levels with poor outcomes ( Figure I in the online-only Data Supplement). After excluding patients with history of coronary heart disease, elevated serum galectin-3 remained significantly associated with risk of primary outcome (Table III in the online-only Data Supplement). Adding serum galectin-3 to a multivariable model containing main conventional risk factors significantly improved predictive ability. Net reclassification index was 18.9% (P<0.001) for primary outcome, 33.7% (P=0.019) for death, and 16.9% (P<0.001) for major disability (Table 2) . Multivariable adjusted for age, sex, time from onset to hospitalization, current smoking, alcohol drinking, systolic blood pressure, white blood cell, baseline NIHSS score, high-sensitivity C-reactive protein, history of hyperlipidemia, history of hypertension, history of coronary heart disease, history of diabetes mellitus, family history of stroke, and use of antihypertensive and lipid-lowering medications. mRS indicates modified Rankin Scale; and NIHSS, National Institutes of Health Stroke Scale.
*Odds of a 1-U higher modified Rankin Scale score.
Discussion
In this study, we found a significant association of elevated baseline galectin-3 level with risks of composite outcomes of death or major disability within 3 months after acute ischemic stroke. This association was independent of established risk factors, including high-sensitivity C-reactive protein, and baseline National Institutes of Health Stroke Scale score. Furthermore, addition of galectin-3 to conventional risk factors significantly improved risk-predictive ability for death or major disability. These results suggested that increased serum galectin-3 could be an independent risk factor of poor outcomes and have prognostic value for death or major disability among patients with ischemic stroke. There have been some studies on the association of galectin-3 with heart failure or cardiovascular disease. [11] [12] [13] However, data from cohort studies on the predictive value of galectin-3 for poor outcomes of ischemic stroke are scarce. Our study is the first prospective cohort study to examine the association between serum galectin-3 and poor outcomes in patients with ischemic stroke. Sensitivity analyses also confirmed these findings. Therefore, the present study supported the association between serum galectin-3 levels and prognosis of ischemic stroke. Further study to optimize and validate the risk prediction model should be warranted.
Animal study showed that galectin-3 was upregulated after hypoxia-ischemic and associated with brain injury in the newborn mice.
14 Galectin-3 expressed in atherosclerotic plaques reflects the degree of plaque inflammation. 15 Our findings supported the hypothesis that serum galectin-3 may have potential role in inflammation, atherosclerosis pathogenesis, and plaque rupture, so high galectin-3 level could be involved in tissue injury and sequent poor outcome.
Routine galectin-3 measurement in patients with ischemic stroke may provide important novel clinical use. In addition, some studies should be encouraged in regarding to galectin-3 inhibitors and whether lowering serum galectin-3 could prevent the poor outcome of ischemic stroke.
Our findings indicated that higher levels of serum galectin-3 in acute ischemic stroke were associated with increased risk of death or major disability at 3 months. Galectin-3 may have potential predictive value in risk stratification of ischemic stroke. Model 1 adjusted for age, sex, time from onset to randomization, current smoking, alcohol drinking, systolic blood pressure, white blood cell, baseline NIHSS score, high-sensitivity C-reactive protein, history of hypertension, history of hyperlipidemia, history of coronary heart disease, history of diabetes mellitus, family history or stroke, and use of antihypertensive and lipid-lowering medications before stroke onset. CI indicates confidence interval; IDI, integrated discrimination index; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and NRI, net reclassification index.
